English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Since 2013, the radionuclide  223 Ra is used in nuclear medicine to prepare radiopharmaceuticals for targeted radiotherapy.  223 Ra is a member of the natural radioactive series of actinium and decays by alpha-particle emission, populating the excited levels of  219 Rn. According to the 2011 nuclear decay data evaluation within the Decay Data Evaluation Project (DDEP), by V.P. Chechev, the half-life of  223 Ra is (11.43 ± 0.03) days. The decay scheme is not considered as fully complete, because of the disagreement between the measured and calculated probabilities of some alpha-transitions and incomplete information on several gamma-ray transitions. New high quality measurements of  223 Ra nuclear decay data were performed and numerous results were published since 2012 and, consequently, an updated nuclear decay data evaluation was undertaken, according to the DDEP procedures. The main results obtained, focusing on the recommended data improvements, are presented and discussed in this paper.

A new evaluation of the nuclear decay data of 223Ra

A new evaluation of the nuclear decay data of ²²³Ra